BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 23316013)

  • 1. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.
    Sieghart W; Hucke F; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Trauner M; Peck-Radosavljevic M
    Hepatology; 2013 Jun; 57(6):2261-73. PubMed ID: 23316013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
    Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W
    J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.
    Hucke F; Sieghart W; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M
    J Hepatol; 2014 Jan; 60(1):118-26. PubMed ID: 24012941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
    Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
    Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
    Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular Carcinoma.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Nishida N; Kitano M; Kudo M
    Oncology; 2015; 89 Suppl 2():4-10. PubMed ID: 26584030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.
    Adhoute X; Penaranda G; Naude S; Raoul JL; Perrier H; Bayle O; Monnet O; Beaurain P; Bazin C; Pol B; Folgoc GL; Castellani P; Bronowicki JP; Bourlière M
    J Hepatol; 2015 Apr; 62(4):855-62. PubMed ID: 25463541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
    Mähringer-Kunz A; Kloeckner R; Pitton MB; Düber C; Schmidtmann I; Galle PR; Koch S; Weinmann A
    Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1017-1025. PubMed ID: 28197830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
    Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M
    Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma.
    Sieghart W; Pinter M; Hucke F; Graziadei I; Schöniger-Hekele M; Müller C; Vogel W; Trauner M; Peck-Radosavljevic M
    Hepatology; 2013 Jun; 57(6):2224-34. PubMed ID: 22961713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
    Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
    J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan.
    Tseng CL; Lai WJ; Huang CJ; Huang YH; Su CW; Lee IC; Tseng HS; Li CP; Lee RC; Lin HC; Chao Y
    Medicine (Baltimore); 2015 Nov; 94(47):e1659. PubMed ID: 26632677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ART score and hepatocellular carcinoma: An appraisal of its applicability.
    Yin W; Ye Q; Wang F; Liang J; Xu B; Zhang X; Zhang Q; Liu Y; Li G; Han T
    Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):705-714. PubMed ID: 27289168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
    Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
    Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.
    Guo Z; Zhong JH; Jiang JH; Zhang J; Xiang BD; Li LQ
    Ann Surg Oncol; 2014 Sep; 21(9):3069-76. PubMed ID: 24728740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching.
    Min YW; Lee JH; Gwak GY; Paik YH; Lee JH; Rhee PL; Koh KC; Paik SW; Yoo BC; Choi MS
    J Gastroenterol Hepatol; 2014 May; 29(5):1043-8. PubMed ID: 24863186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of long-term survival in hepatocellular carcinomas: A longitudinal follow-up of 108 patients with small tumors.
    Chang HC; Lin YM; Yen AM; Chen SL; Wu WY; Chiu SY; Fann JC; Lin YS; Chen HH; Liao CS
    Anticancer Res; 2013 Nov; 33(11):5171-8. PubMed ID: 24222166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Azemoto R; Shinozaki M; Yoshikawa M; Yokosuka O
    PLoS One; 2015; 10(4):e0125244. PubMed ID: 25919025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
    Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.